Edition:
United Kingdom

People: Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

5.89USD
21 May 2019
Change (% chg)

$-0.09 (-1.51%)
Prev Close
$5.98
Open
$5.89
Day's High
$5.89
Day's Low
$5.89
Volume
603
Avg. Vol
13,273
52-wk High
$10.51
52-wk Low
$3.35

Drummond, Daryl 

Dr. Daryl C. Drummond, Ph.D is Head of Research, since March 2017. Dr. Drummond served as our Vice President of Discovery from July 2014 to March 2017 and Senior Director of Nanotherapeutics from October 2009 to July 2014. Dr. Drummond previously served as Director of Liposome Research and Development at Hermes BioSciences, Inc., a biotechnology company that was acquired by Merrimack in October 2009. Prior to joining Hermes BioSciences, Inc. in 2000, Dr. Drummond was a post-doctoral fellow at California Pacific Medical Center, where he focused on lipid-based drug delivery systems. Dr. Drummond is a principal inventor for many of Merrimack’s nanotechnology-based drugs and platform technologies, including ONIVYDE® , which Merrimack sold to Ipsen S.A., or Ipsen, in April 2017. Dr. Drummond holds a Ph.D. in biochemistry and a B.S. from Indiana University.

Basic Compensation

Total Annual Compensation, USD 362,769
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 401,852
Fiscal Year Total, USD 764,621

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --